Search Results

You are looking at 41 - 50 of 115 items for :

  • "aromatase inhibitor" x
  • Refine by Access: All x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

-line versus second- and subsequent-line settings. Preferred First-Line Therapy for HR-Positive, HER2-Negative Breast Cancer Aromatase Inhibitor in Combination With Cyclin-Dependent Kinase 4/6 Inhibitor In postmenopausal women or premenopausal women receiving

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund

has been suggested that users of the hormone therapy tamoxifen are at an increased risk of venous thromboembolism compared with aromatase inhibitor users, but at a decreased risk of other cardiovascular outcomes, such as coronary heart disease. 36 – 38

Full access

Charles J. Ryan and Eric J. Small

Santen RJ PG Fisch MJ Myers CE . Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma . Cancer 2001 ; 92 : 2095 – 2101 . 32 Smith M Kaufman D George D .: Selective aromatase inhibition

Full access

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

. Specifically, Charlson et al assessed the rates of initiation of aromatase inhibitors (AIs) versus tamoxifen in the treatment of postmenopausal women with breast cancer between 2006 and 2007. During this study period, AI therapy was recommended as part of

Full access

Rachel M. Layman

for treatment of this patient population: palbociclib, ribociclib, and abemaciclib. CDK4/6 inhibitor therapy in combination with aromatase inhibitors (AIs) and the selective estrogen receptor degrader fulvestrant have demonstrated efficacy for

Full access

Mindy E. Goldman

hormone replacement therapy tend to abruptly stop when diagnosed with endocrine-dependent cancers; and vasomotor symptoms are common with hormonal drugs such as tamoxifen or aromatase inhibitors. For Dr. Goldman, the key is to be sure that menopausal

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

levels or activity of endogenous estrogen provide a noncytotoxic alternative systemic therapy option for treating hormone-sensitive uterine sarcomas. Hormonal agents used in uterine sarcomas include aromatase inhibitors (AIs), progestins (eg

Full access

Juan P. Cata and Daniel D. Kim

concurrent use of side effect controlling medications among women on aromatase inhibitors [published online October 26, 2020] . J Womens Health (Larchmt) , doi: 10.1089/jwh.2020.8493 JUAN P. CATA, MD Juan P. Cata, MD, is an Associate Professor in the

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2019

Featured Updates to the NCCN Guidelines

Tara Sanft, Crystal S. Denlinger, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Divya Koura, Robin M. Lally, Terry S. Langbaum, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

specialists. An external proposal included a request for a section specifically addressing aromatase inhibitor (AI)–induced arthralgias based on new data and the large number of survivors affected by this syndrome. A double-blind phase III RCT, which included

Full access

Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick

endocrine therapy with aromatase inhibitors (AIs) for women with hormone receptorpositive breast cancer is a prime example. Although some data support AI use for 5 years based on randomized clinical trials, evidence is still unclear beyond this duration, and